Novo Nordisk Slides as Forecast Boost Fails to Impress

Novo Nordisk A/S raised its forecasts for the second time this year, citing higher expectations for its obesity and diabetes drug sales, though the magnitude of the increase failed to...

By Naomi Kresge · Bloomberg Markets

Novo Nordisk A/S raised its forecasts for the second time this year, citing higher expectations for its obesity and diabetes drug sales, though the magnitude of the increase failed to impress investors.